Efficacy and safety of single-agent axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): a phase II trial

被引：0
|
作者：
Von Pawel, J. [1 ]
Larson, T. [2 ]
Ou, S. I. [3 ]
Limentani, S. A. [4 ]
Sandler, A. B. [5 ]
Vokes, E. E. [6 ]
Kim, S.
Liau, K. F.
Bycott, P. W. [7 ]
Schiller, J. H. [8 ]
机构：
[1] Asklepios Fachklin Lungenkrankheiten, Abt Onkol, Gauting, Germany
[2] Hubert H Humphrey Canc Ctr, Robbinsdale, MN USA
[3] Chao Family Comprehens Canc Ctr, Orange, CA USA
[4] Blumenthal Canc Ctr, Carolinas Hematol Oncol Assoc, Charlotte, NC USA
[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[6] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[7] Pfizer Inc, San Diego, CA USA
[8] Univ Texas Southwestern, Dallas, TX USA
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)71379-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6551
引用
收藏
页码：373 / 373
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial
    Schiller, J. H.
    Larson, T.
    Ou, S. I.
    Limentani, S. A.
    Sandler, A. B.
    Vokes, E. E.
    Kim, S.
    Liau, K. F.
    Bycott, P. W.
    Olszanski, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Axitinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors
    Martin, L. P.
    Kozloff, M. F.
    Krzakowski, M.
    Samuel, T. A.
    Rado, T. A.
    Tarazi, J.
    Rosbrook, B.
    Tortorici, M.
    Olszanski, A. J.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers
    Cohen, E. E.
    Vokes, E. E.
    Rosen, L. S.
    Kies, M. S.
    Forastiere, A. A.
    Worden, F. P.
    Kane, M. A.
    Liau, K. F.
    Shalinsky, D. R.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase 2 study of axitinib (AG-013736; AG) in patients (pts) with advanced thyroid cancers
    Cohen, E.
    Vokes, E. E.
    Rosen, L. S.
    Kies, M. S.
    Forastiere, A. A.
    Worden, F. P.
    Kane, M. A.
    Liau, K. F.
    Shalinsky, D. R.
    Cohen, R. B.
    EJC SUPPLEMENTS, 2007, 5 (04): : 326 - 326
  • [5] Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib
    Rini, B. I.
    Wilding, G. T.
    Hudes, G.
    Stadler, W. M.
    Kim, S.
    Tarazi, J. C.
    Bycott, P. W.
    Liau, K. F.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib
    Rini, B.
    Wilding, G.
    Hudes, G.
    Stadler, W. M.
    Kim, S.
    Tarazi, J.
    Bycott, P.
    Liau, K.
    Dutcher, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 300 - 300
  • [7] PHASE I STUDY OF AXITINIB (AG-013736) IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS (PTS) WITH ADVANCED SOLID TUMOURS
    Martin, L. P.
    Kozloff, M.
    Herbst, R. S.
    Samuel, T. A.
    Kim, S.
    Rosbrook, B.
    Tortorici, M.
    Tarazi, J.
    Olszanski, A. J.
    Cohen, R. B.
    ANNALS OF ONCOLOGY, 2008, 19 : 157 - 157
  • [8] A phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer.
    Kim, S.
    Rosen, L. S.
    Cohen, E. E.
    Cohen, R. B.
    Forastiere, A.
    Silva, A. M.
    Liau, K. F.
    Archer, R. L.
    Bycott, P.
    Vokes, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 287S - 287S
  • [9] Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer
    Jean-Philippe Spano
    Malcolm J. Moore
    Yazdi K. Pithavala
    Alejandro D. Ricart
    Sinil Kim
    Olivier Rixe
    Investigational New Drugs, 2012, 30 : 1531 - 1539
  • [10] Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer
    Spano, Jean-Philippe
    Moore, Malcolm J.
    Pithavala, Yazdi K.
    Ricart, Alejandro D.
    Kim, Sinil
    Rixe, Olivier
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1531 - 1539
12345